Details of the Drug Combination

General Information of Drug Combination (ID: DCGLQVN)

Drug Combination Name
Paromomycin Dihydroergotamine
Indication
Disease Entry Status REF
Chronic myelogenous leukemia Investigative [1]
Component Drugs Paromomycin   DM1AGXN Dihydroergotamine   DM5IKUF
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: KBM-7
Zero Interaction Potency (ZIP) Score: 12.47
Bliss Independence Score: 12.47
Loewe Additivity Score: 26.81
LHighest Single Agent (HSA) Score: 26.81

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Paromomycin
Disease Entry ICD 11 Status REF
Amoebiasis 1A36 Approved [2]
Hepatic coma N.A. Approved [2]
Intestinal amebiasis 1A36 Approved [3]
Paromomycin Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Staphylococcus 30S ribosomal subunit (Stap-coc pbp2) TTQ8KVI F4NA87_STAAU Binder [6]
------------------------------------------------------------------------------------
Paromomycin Interacts with 1 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Serine-protein kinase ATM (ATM) OTQVOHLT ATM_HUMAN Increases Expression [7]
------------------------------------------------------------------------------------
Indication(s) of Dihydroergotamine
Disease Entry ICD 11 Status REF
Cluster headache 8A81.0 Approved [4]
Migraine 8A80 Approved [5]
Migraine disorder N.A. Approved [4]
Dihydroergotamine Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Dopamine D2 receptor (D2R) TTEX248 DRD2_HUMAN Agonist [8]
------------------------------------------------------------------------------------
Dihydroergotamine Interacts with 1 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [9]
------------------------------------------------------------------------------------

References

1 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2 Paromomycin FDA Label
3 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 064171.
4 Dihydroergotamine FDA Label
5 Sustained pain relief with dihydroergotamine in migraine is potentially due to persistent binding to 5-HT1B and 5-HT1D receptors. . The Journal of Headache and Pain 201314(Suppl 1):P75.
6 Aminoglycoside association pathways with the 30S ribosomal subunit. J Phys Chem B. 2009 May 21;113(20):7322-30.
7 Correction of ATM gene function by aminoglycoside-induced read-through of premature termination codons. Proc Natl Acad Sci U S A. 2004 Nov 2;101(44):15676-81. doi: 10.1073/pnas.0405155101. Epub 2004 Oct 21.
8 Current and prospective pharmacological targets in relation to antimigraine action. Naunyn Schmiedebergs Arch Pharmacol. 2008 Oct;378(4):371-94.
9 CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes. Br J Clin Pharmacol. 2004 Mar;57(3):287-97.